ABRYSVO

Active ingredients

The drug ABRYSVO contains one active pharmaceutical ingredient (API):

RSV glycoprotein F antigen is designed to enhance antigen-specific cellular immune response and neutralizing antibodies response in individuals with pre-existing immunity against RSV. The adjuvant AS01E facilitates the recruitment and activation of antigen presenting cells carrying vaccine-derived antigens in the draining lymph node, which in turn leads to the generation of RSVPreF3-specific CD4+ T cells.

Read about RSV glycoprotein F antigen

Medication package inserts

Below package inserts are available for further reading:

Title
Type
Country
ABRYSVO Powder and solvent for solution for injection
Summary of Product Characteristics (SPC)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
J07BX05
J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BX Other viral vaccines
Discover more medicines within J07BX05

Authorization and marketing

This brand name is authorized in the following countries: Austria Lithuania Romania United States

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
LT
Valstybinė vaistų kontrolės tarnyba
Identifier(s): 1097701, 1097702, 1097703, 1097704, 1097705, 1097706
RO
Agenția Națională a Medicamentului și a Dispozitivelor Medicale
Identifier(s): W69758001, W69758002, W69758003, W69758004, W69758005, W69758006
US
FDA, National Drug Code
Identifier(s): 0069-0207, 0069-0250, 0069-0344